The technology offer: a generic package of competitive know how

The BBG offers the technology for long-term collaborative efforts with other research groups and innovative companies with the goal to amplify the range of generic solutions and the frontiers of basic science.

The group seeks the colaboration of private capital and small and medium enterprises for product development and spin offs.

The market: untampered opportunities

DNA biochip arrays: there is an existing market of more than $500 millions although the tools are not yet perfected. This market is mainly in pharmacogenomics, expression profiling and toxicology screening. The diagnostics market is virtually virgin since the cost of the existing solutions is prohibitive, especially for point of care or home diagnostics.

Immunosensors: the combined immunoassay market for applications is estimated to be more than $1000 millions. Virtually all existing immunoassays and several new ones for "niche" applications are reducible to immunosensors. The lack of fast, low cost, and quantitative immunosensors does not permit market penetration.

Enzyme sensors: the large diagnostics companies cannot address small (less than $100 millions but more than $10 millions) market needs and this area is left un-exploited. Even in the traditional markets (e.g. glucose diagnostics) minimally invasive human diagnostics and reliability are developed at levels below expectations and possibilities. In the food industry and environmental monitoring and control, enzyme sensors have not made their penetration.

The bioelectronic interface: generic technologies establishing the biological-microelectronic communication have a vast array of applications in telemedicine, miniature biofuel cells, fine chemicals production and the neuronal-computer communication. It is difficult to estimate the size of these markets of the future but they are essentially open for penetration.